HomeCompareALPN vs MO

ALPN vs MO: Dividend Comparison 2026

ALPN yields 3.08% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $55.8K in total portfolio value· pulled ahead in Year 5
10 years
ALPN
ALPN
● Live price
3.08%
Share price
$64.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.4K
Annual income
$375.35
Full ALPN calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — ALPN vs MO

📍 MO pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALPNMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALPN + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALPN pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALPN
Annual income on $10K today (after 15% tax)
$261.66/yr
After 10yr DRIP, annual income (after tax)
$319.05/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $25,316.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALPN + MO for your $10,000?

ALPN: 50%MO: 50%
100% MO50/50100% ALPN
Portfolio after 10yr
$52.2K
Annual income
$15,267.25/yr
Blended yield
29.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ALPN
Analyst Ratings
9
Buy
6
Hold
Consensus: Buy
Price Target
$55.00
-15.3% upside vs current
Range: $44.00 — $65.00
Altman Z
65.0
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALPN buys
0
MO buys
0
No recent congressional trades found for ALPN or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALPNMO
Forward yield3.08%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$24.4K$80.1K
Annual income after 10y$375.35$30,159.17
Total dividends collected$3.4K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$55.00$61.25

Year-by-year: ALPN vs MO ($10,000, DRIP)

YearALPN PortfolioALPN Income/yrMO PortfolioMO Income/yrGap
1$11,008$307.83$10,570$780.30+$438.00ALPN
2$12,095$316.69$11,381$1,032.90+$714.00ALPN
3$13,267$325.21$12,535$1,392.73+$732.00ALPN
4$14,529$333.38$14,193$1,920.91+$336.00ALPN
5← crossover$15,887$341.21$16,618$2,723.68$731.00MO
6$17,348$348.70$20,263$3,993.80$2.9KMO
7$18,918$355.85$25,936$6,098.36$7.0KMO
8$20,605$362.67$35,166$9,775.01$14.6KMO
9$22,417$369.17$51,026$16,597.78$28.6KMO
10$24,361$375.35$80,113$30,159.17$55.8KMO

ALPN vs MO: Complete Analysis 2026

ALPNStock

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Full ALPN Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ALPN vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALPN vs SCHDALPN vs JEPIALPN vs OALPN vs KOALPN vs MAINALPN vs PMALPN vs BTIALPN vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.